Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a research note released on Monday morning,Wall Street Zen reports.

A number of other brokerages have also commented on TVRD. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a research note on Wednesday, July 8th. BTIG Research reduced their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. Finally, Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Trading Down 3.8%

Shares of TVRD opened at $1.00 on Monday. Tvardi Therapeutics has a 52 week low of $0.93 and a 52 week high of $7.23. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $2.51.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Sell-side analysts predict that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in Tvardi Therapeutics during the 2nd quarter worth $34,000. Susquehanna International Group LLP acquired a new position in Tvardi Therapeutics during the 2nd quarter worth about $63,000. Finally, BlackRock Inc. acquired a new position in Tvardi Therapeutics during the 2nd quarter worth about $181,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.